DOI QR코드

DOI QR Code

Effects of Ubiquitin-conjugating Enzyme 2C on Invasion, Proliferation and Cell Cycling of Lung Cancer Cells

  • Tang, Xiao-Kui (Department of Respiratory Disease, The First Affiliated Hospital of Chongqing Medical University) ;
  • Wang, Ke-Jian (Department of Anatomy, Chongqing Medical University) ;
  • Tang, Yu-Kui (Department of Dematology, The First Affiliated Hospital of Chongqing Medical University) ;
  • Chen, Li (Department of Thoracocardiac Surgery, The First Affiliated Hospital of Chongqing Medical University)
  • Published : 2014.04.01

Abstract

The aims of this study were to investigate the influence of ubiquitin- conjugating enzyme E2C (UBE2C) on biological behavior of lung cancer cells. Using MTT, flow cytometry and invasion assays, we detected UBE2C expression and evaluated its biological properties in these cells, including effects on proliferation, the cell cycle profile and invasive capability. Compared with control cells, the UBE2C transfected cells demonstrated increased cellular proliferation (p<0.05). UBE2C transfected cells also had a lower percentage in G1 phase and a higher percentage in S phase (p<0.05). Importantly, the UBE2C transfected cells had a notable enhancement of cell numbers penetrating the basement membrane compared with the control group (p<0.05). Ectopic up-regulation UBE2C promoted the growth of lung cancer cells in vivo. Furthermore, we found UBE2C increased the expression of cyclin D1 and MMP-2. These results show UBE2C may represent a potential therapeutic target for lung cancer.

Keywords

UBE2C;proliferation;invasion;lung cancer

Acknowledgement

Supported by : Chongqing Municipal Education Commission

References

  1. Zhao L, Jiang L, Wang L, et al (2012). UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 1951-61. https://doi.org/10.1007/s00432-012-1275-2
  2. Zahir ST, Mirtalebi M (2012). Survival of patients with lung cancer, Yazd, Iran. Asian Pacific J Cancer Prev, 13, 4387- 91. https://doi.org/10.7314/APJCP.2012.13.9.4387
  3. Nagase H, Woessnerjr JF (1999). Matrix metalloproteinases. J Biol Chem, 274, 21491-4. https://doi.org/10.1074/jbc.274.31.21491
  4. Jiang L, Bao Y, Luo C, et al (2010). Knockdown of ubiquitin -conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro. J Cancer Res Clin Oncol, 136, 211-7. https://doi.org/10.1007/s00432-009-0651-z
  5. Jiang L, Huang CG, Lu YC, et al (2008). Expression of ubiquitinconjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res, 1201, 161-6. https://doi.org/10.1016/j.brainres.2008.01.037
  6. Lin J, Raoof DA, Wang Z, et al (2006). Expression and effect of inhibition of the ubiquitinconjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia, 8, 1062-71. https://doi.org/10.1593/neo.05832
  7. Okamoto Y, Ozaki T, Miyazaki K, et al (2003). UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res, 63, 4167-73.
  8. Pallante P, Berlingieri MT, Troncone G, et al (2005). UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer, 93, 464-71. https://doi.org/10.1038/sj.bjc.6602721
  9. Perrotta I, Bruno L, Maltese L, et al (2012). Immunohistochemical analysis of the ubiquitin -conjugating enzyme UbcH10 in lung cancer: a useful tool for diagnosis and therapy. J Histochem Cytochem, 60, 359-65. https://doi.org/10.1369/0022155412439717
  10. Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM (2001). Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell, 105, 645-55. https://doi.org/10.1016/S0092-8674(01)00361-0
  11. Rizzi A, Tondini M, Rocco G, et al (1990). Lung cancer with a single brain metastasis: therapeutic options. Tumori, 76, 579-89.
  12. Troncone G, Guerriero E, Pallante P, et al (2009). UbcH10 expression in human lymphomas. Histopathology, 54, 731-40. https://doi.org/10.1111/j.1365-2559.2009.03296.x
  13. Westermarck J, Kahari VM (1999). Regulation of matrix metallo-proteinase expression in tumor invasion. FASEB J, 13, 781-92. https://doi.org/10.1096/fasebj.13.8.781
  14. Bhaskarapillai B, Kumar SS, Balasubramanian S (2012). Lung cancer in Malabar Cancer Center in Kerala-a descriptive analysis. Asian Pacific J Cancer Prev, 13, 4639-43. https://doi.org/10.7314/APJCP.2012.13.9.4639
  15. Berlingieri MT, Pallante P, Guida M, et al (2007). UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene, 26, 2136-40. https://doi.org/10.1038/sj.onc.1210010
  16. Berlingieri MT, Pallante P, Guida M, et al (2007). UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer, 43, 2729-35. https://doi.org/10.1016/j.ejca.2007.09.003
  17. Bernhard EJ, Gruber SB, Muschel RJ (1994). Direct evidence linking expression of matrix metalloproteinase 9 to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA, 91, 4293-7. https://doi.org/10.1073/pnas.91.10.4293
  18. Bose MV, Gopisetty G, Selvaluxmy G, Rajkumar T (2012). Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation. Int J Radiat Biol, 88, 629-34. https://doi.org/10.3109/09553002.2012.702299
  19. Chen S, Chen Y, Hu C, et al (2010). Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol, 136, 419-26. https://doi.org/10.1007/s00432-009-0672-7
  20. Fujita T, Ikeda H, Taira N, et al (2009). Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer, 9, 87-96. https://doi.org/10.1186/1471-2407-9-87
  21. Hsu JY, Reimann JD, Sorensen CS, Lukas J, Jackson PK (2002). E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC (Cdh1). Nat Cell Biol, 4, 358-66. https://doi.org/10.1038/ncb785
  22. Ieta K, Ojima E, Tanaka F, et al (2007). Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer, 121, 33-8. https://doi.org/10.1002/ijc.22605
  23. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
  24. Bavi P, Uddin S, Ahmed M, et al (2011). Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol, 178, 2109-20. https://doi.org/10.1016/j.ajpath.2011.01.034

Cited by

  1. UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53 vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3723
  2. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data vol.17, pp.1, 2017, https://doi.org/10.1186/s12935-017-0455-1
  3. Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression vol.12, pp.3, 2016, https://doi.org/10.3892/ol.2016.4860
  4. Oral administration of oat beta-glucan preparations of different molecular weight results in regulation of genes connected with immune response in peripheral blood of rats with LPS-induced enteritis pp.1436-6215, 2018, https://doi.org/10.1007/s00394-018-1838-3
  5. UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability vol.9, pp.1663-9812, 2018, https://doi.org/10.3389/fphar.2018.00847